About Palvella Therapeutics

Palvella Therapeutics develops the QTORIN™ platform, a patented topical drug delivery system designed to achieve therapeutic concentrations in the deep layers of the skin for treating rare genetic dermatological diseases. The company addresses the lack of FDA-approved therapies for these conditions, aiming to provide effective treatment options for patients suffering from mTOR-driven skin disorders.

<problem> Many rare genetic skin diseases lack FDA-approved therapies, leaving patients without effective treatment options. Developing topical treatments for these conditions is challenging due to difficulties in achieving therapeutic drug concentrations in the deep layers of the skin while minimizing systemic absorption. </problem> <solution> Palvella Therapeutics is developing the QTORIN™ platform, a patented topical drug delivery system designed to deliver therapeutic concentrations of drugs to the deep layers of the skin. The QTORIN™ platform addresses the challenges of topical drug delivery by achieving both effective drug penetration and chemical stability. Palvella's initial product candidate, QTORIN 3.9% rapamycin anhydrous gel, has the potential to impact patients living with mTOR-driven rare genetic skin diseases. </solution> <features> - QTORIN™ platform designed for rapid delivery of therapies to deep skin layers. - Topical application minimizes systemic absorption compared to oral medications. - QTORIN™ platform has received Fast Track and Breakthrough Therapy designations from the FDA. </features> <target_audience> The primary target audience includes individuals suffering from rare genetic skin diseases, particularly those with mTOR-driven disorders, and the healthcare professionals who treat them. </target_audience>

What does Palvella Therapeutics do?

Where is Palvella Therapeutics located?

Palvella Therapeutics is based in Wayne, United States.

When was Palvella Therapeutics founded?

Palvella Therapeutics was founded in 2015.

Location

Wayne, United States

Founded

2015

Employees

27 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Palvella Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

palvellatx.com 2K+

Founded 2015 – Wayne, United States

Funding

No funding information available.

Team (25+)

No team information available.

Company Description

Problem

Many rare genetic skin diseases lack FDA-approved therapies, leaving patients without effective treatment options. Developing topical treatments for these conditions is challenging due to difficulties in achieving therapeutic drug concentrations in the deep layers of the skin while minimizing systemic absorption.

Solution

Palvella Therapeutics is developing the QTORIN™ platform, a patented topical drug delivery system designed to deliver therapeutic concentrations of drugs to the deep layers of the skin. The QTORIN™ platform addresses the challenges of topical drug delivery by achieving both effective drug penetration and chemical stability. Palvella's initial product candidate, QTORIN 3.9% rapamycin anhydrous gel, has the potential to impact patients living with mTOR-driven rare genetic skin diseases.

Features

QTORIN™ platform designed for rapid delivery of therapies to deep skin layers.

Topical application minimizes systemic absorption compared to oral medications.

QTORIN™ platform has received Fast Track and Breakthrough Therapy designations from the FDA.

Target Audience

The primary target audience includes individuals suffering from rare genetic skin diseases, particularly those with mTOR-driven disorders, and the healthcare professionals who treat them.